Abstract

Retrospective Analysis of the Safety and Efficacy of High-dose Interleukin-2 After Prior Tyrosine Kinase Inhibitor Therapy in Patients with Advanced Renal Cell Carcinoma

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title
Journal
Date
Author
ESMO Clinical Practice Guideline update on the use of immunotherapy in early stage and advanced renal cell carcinoma
T Powles ... G De Velasco
Annals of oncology : official journal of the European Society for Medical Oncology | VOL. 32
T Powles, et. al.T Powles ... G De Velasco
28 Sep 2021
Cabozantinib in advanced renal cell carcinoma: A phaseII, open-label, single-arm study of Japanese patients.
Yoshihiko Tomita ... Yasuhide Miyoshi
International journal of urology : official journal of the Japanese Urological Association | VOL. 27
Yoshihiko Tomita, et. al.Yoshihiko Tomita ... Yasuhide Miyoshi
12 Aug 2020
Comparison of the Clinical Outcome of Ramucirumab for Unresectable Hepatocellular Carcinoma with That of Prior Tyrosine Kinase Inhibitor Therapy
Kei Amioka ... Kazuaki Chayama
Oncology | VOL. 99
Kei Amioka, et. al.Kei Amioka ... Kazuaki Chayama
05 Mar 2021
Retrospective analysis of the safety and efficacy of high-dose interleukin-2 after prior tyrosine kinase inhibitor therapy in patients with advanced renal cell carcinoma.
Elaine T Lam ... Neeraj Agarwal
Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy | VOL. 37
Elaine T Lam, et. al.Elaine T Lam ... Neeraj Agarwal
13 Aug 2014
View more papers

More From: Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy

Paper Title
Journal
Date
Author
Corneal Transplant Rejection Following Durvalumab Therapy in a Patient With NSCLC: A Case Report.
Luise Froessl ... Jonathan Dowell
Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy | VOL. -
Luise Froessl, et. al.Luise Froessl ... Jonathan Dowell
30 Jul 2024
Blood Tumor Mutational Burden Alone Is Not a Good Predictive Biomarker for Response to Immune Checkpoint Inhibitors in Patients With Gastrointestinal Tumors.
James Yu ... Richard Kim
Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy | VOL. -
James Yu, et. al.James Yu ... Richard Kim
16 Jul 2024
HES6 Mediates Oxidative Phosphorylation Pathway to Promote Immune Infiltration of CD8+ T Cells in Lung Adenocarcinoma.
Zhoumiao Chen ... Zhao Chen
Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy | VOL. -
Zhoumiao Chen, et. al.Zhoumiao Chen ... Zhao Chen
15 Jul 2024
Generation and Characterization of Ex Vivo Expanded Tumor-infiltrating Lymphocytes From Renal Cell Carcinoma Tumors for Adoptive Cell Therapy.
David J Einstein ... David F Mcdermott
Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy | VOL. -
David J Einstein, et. al.David J Einstein ... David F Mcdermott
15 Jul 2024
View more papers